India's pharma exports unlikely to be affected amid Tylenol debate: Experts

Data shows India's paracetamol exports to the US are modest, accounting for less than one per cent of API shipments, despite global attention on the Tylenol controversy

Amid controversy over President Donald Trump’s comments linking the use of Tylenol and other related paracetamol products by pregnant women to autism in children, experts and industry executives say that since India’s export of the drug to the US is less, it will hardly affect the country’s pharma exports to America.

 

Nikkhil Masurkar, CEO at Entod Pharmaceuticals, said paracetamol is likely to account for a low single-digit share of India’s US-bound pharma exports and that the recent clinician messaging by the US Food and Drug Administration (FDA) is unlikely to dent the overall US paracetamol demand materially, so India’s export